Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study

Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study

Bibliographic Details
Main Authors: F. Barata, H. Queiroga, E. Teixeira, T. Almodovar, M. Soares, B. Parente, J.C. Mellidez, P. Alves, A. Antunes
Format: Article
Language:English
Published: Elsevier España 2021-03-01
Series:Pulmonology
Online Access:http://www.sciencedirect.com/science/article/pii/S2531043720302063

Internet

http://www.sciencedirect.com/science/article/pii/S2531043720302063

Similar Items